unit
state
major
pharmaceut
compani
activ
acquir
terrestri
marin
natur
product
extract
terrestri
marin
macroorgan
microorgan
cultur
terrestri
marin
microorgan
purpos
find
new
small
molecul
lead
structur
knowledg
mani
major
pharmaceut
compani
japan
europ
involv
well
us
govern
provid
substanti
support
sinc
academ
research
biolog
activ
marinederiv
compound
govern
agenc
includ
nation
institut
health
nih
nation
cancer
institut
nci
nation
institut
allerg
infecti
diseas
niaid
well
nation
sea
grant
colleg
programn
ocean
atmospher
administr
noaa
persino
persino
increas
interest
us
govern
biolog
activ
marin
terrestri
natur
product
recent
led
exampl
format
nih
nation
cooper
natur
product
drug
discoveri
group
includ
promin
academ
lab
engag
marin
terrestri
natur
product
research
sever
major
pharmaceut
compani
repres
nih
purpos
discov
new
structur
lead
activ
cancer
human
immunodefici
viru
hiv
opportunist
infect
associ
acquir
immun
defici
syndrom
aid
persino
persino
strong
program
natur
product
research
histor
exist
europ
japan
tremend
level
interest
japan
develop
marin
resourc
recent
led
govern
industri
univers
undertak
major
long
term
initi
marin
biotechnolog
includ
effort
produc
marinederiv
pharmaceut
persino
persino
fact
two
major
facil
recent
built
expressli
purpos
one
citi
kamaishi
take
advantag
organ
found
cold
current
japan
northeast
coast
citi
shimizu
current
warm
current
interest
natur
product
sourc
therapeut
agent
surpris
consid
major
role
natur
materi
natur
product
play
develop
modern
therapeut
throughout
year
record
histori
medicin
includ
record
china
kim
middl
east
south
america
europ
mexico
primari
sourc
medicin
consist
terrestri
plant
form
herb
prepar
galen
medicin
burger
inde
develop
modern
therapeut
report
begun
digitali
mixtur
steroid
cardiac
glycosid
sever
plant
includ
purpl
foxglov
digitali
purpurea
use
british
physician
treat
dropsi
condit
caus
congest
heart
failur
character
accumul
fluid
burger
sinc
numer
natur
occur
compound
purifi
use
medicin
health
purpos
includ
plant
metabolit
steroid
hormon
androgen
estrogen
progestin
glucocorticoid
cortison
pituitari
hormon
antidiuret
hormon
adh
adrenocorticotropin
acth
vasopressin
oxytocin
vitamin
vitamin
cod
liver
oil
physician
desk
refer
scrip
guyton
recognit
microbi
basi
infecti
diseas
latter
half
discoveri
lysi
factor
penicillin
penicilliwn
notatum
stage
eventu
set
use
microorganismderiv
natur
product
medicin
initi
antibiot
see
discuss
reuben
wittcoff
shortli
public
studi
penicillin
intens
search
ensu
find
new
better
microorganismderiv
antibiot
burger
near
sewag
outfal
mediterranean
antibioticproduc
fungi
cephalosporium
acremonium
isol
abraham
abraham
newton
biolog
activ
compon
name
cephalosporin
structur
relat
penicillin
reuben
wittcoff
capril
would
claim
marinederiv
rinehart
torr
cephalosporin
turn
significantli
activ
penicillin
gramneg
microorgan
resist
degrad
staphylococc
capril
cephalosporin
broadli
use
therapeut
well
prophylact
prior
surgeri
kaiser
sinc
first
member
three
gener
cephalosporin
introduc
cephalosporin
market
capril
numer
addit
microorganismderiv
compound
use
develop
antibiot
major
diseas
area
scrip
hall
notabl
exampl
immunosuppress
agent
cyclosporin
dreyfuss
et
al
kino
et
al
kino
et
al
numer
antitumor
antibiot
includ
bleomycin
calicheamicin
esperamicin
mitomycin
c
actinomycin
william
et
al
refer
therein
cholesterollow
agent
mevinolin
albert
et
al
toward
end
approxim
top
hospit
drug
total
us
dollar
sale
deriv
natur
sourc
mostli
antibiot
approxim
top
wide
prescrib
ethic
drug
also
deriv
natur
sourc
ie
antibiot
ferment
broth
alkaloid
plant
reuben
wittcoff
microorganismderiv
antibiot
also
among
largest
volum
pharmaceut
consum
approxim
total
annual
tonnag
vitamin
aspirinacetaminophen
compris
remain
tonnag
ferment
yield
antibiot
except
chloramphenicol
yield
biotechnologyrel
product
well
contrast
chemic
synthesi
semisynthesi
yield
major
heart
drug
central
nervou
system
agent
antihistamin
analges
antiinflammatori
drug
world
ocean
repres
enorm
resourc
discoveri
potenti
therapeut
agent
ultim
yield
mani
pharmaceut
lead
obtain
terrestri
biospher
predict
base
follow
inform
world
ocean
cover
earth
surfac
barn
contain
well
invertebr
algal
speci
georg
georg
winston
exist
nearli
speci
winston
alga
seawe
green
chlorophyta
red
rhodophyta
brown
phaeophyta
group
marin
invertebr
new
chemic
structur
biolog
activ
report
spong
porifera
cnidarian
coelenter
coral
octocor
includ
sea
fan
hydroid
sea
anemon
nemertean
worm
bryozoan
ascidian
tunic
includ
sea
squirt
mollusc
sea
snail
sea
slug
echinoderm
brittlestar
sea
urchin
starfish
sea
cucumb
two
major
anim
phyla
repres
aquat
environ
eight
phyla
includ
cnidaria
porifera
bryozoa
echinodermata
exclus
aquat
primarili
marin
barn
term
known
speci
habitat
exclud
insect
world
ocean
repres
greatest
resourc
new
natur
product
munro
et
al
inde
sinc
approxim
new
marin
natur
product
report
rel
small
number
research
lab
faulkner
faulkner
faulkner
faulkner
faulkner
faulkner
faulkner
unfortun
small
percentag
compound
fulli
evalu
biolog
activ
relev
human
evalu
clinic
relev
assay
clinic
relev
assay
loos
defin
one
posit
potent
respons
would
elicit
seriou
interest
pharmaceut
compani
organ
suffici
resourc
experi
success
develop
therapeut
agent
nonmov
sessil
marin
invertebr
eg
figur
poriferademospongia
spong
coelenterata
sea
fan
soft
coral
hard
coral
alga
figur
rhodophyta
red
alga
phaeophyta
brown
alga
chlorophyta
green
alga
contain
primit
immun
system
plant
microorgan
found
terrestri
biospher
vide
supra
hypothes
hall
william
et
al
terrestri
analog
marin
organ
contain
sophist
immun
system
use
natur
product
allelochem
whittak
feeni
respons
varieti
ecolog
behavior
physiolog
factor
baku
et
al
davi
et
al
geiselman
mcconnel
mcconnel
et
al
hay
fenic
hay
et
al
paul
order
surviv
prolifer
environ
primit
organ
must
produc
compound
use
chemic
defend
andor
assist
prevent
overgrowth
foul
metabolit
also
therapeut
potenti
human
diseas
specif
interact
receptor
enzym
hall
william
et
al
rational
specif
biolog
activ
special
vertebr
cell
humor
nervou
immun
vascular
system
appear
rel
recent
evolut
transmitt
molecul
use
hormon
neuropeptid
biolog
respons
modifi
well
allelochem
may
arisen
much
earlier
unicellular
simpl
multicellular
organ
gilbert
nisbet
porter
roth
et
al
inde
believ
alga
bacteria
exist
possibl
billion
year
ago
rel
rhodophyta
isghhum
figur
phylogenet
tree
reproduc
permiss
scheuer
simpl
invertebr
exist
approxim
billion
year
wherea
first
primit
vertebr
develop
million
year
ago
earli
mammal
exist
million
year
tullar
rather
short
period
time
year
rel
intens
effort
made
isol
identifi
new
marinederiv
natur
product
even
shorter
period
time
perhap
year
major
research
effort
area
clearli
shift
find
new
compound
find
biolog
activ
compound
clinic
relev
assay
surpris
hand
compound
made
clinic
trial
beyond
among
compound
bryostatin
didemnin
b
manoalid
pseudopterosin
araa
arac
synthet
analog
marin
spongederiv
compound
numer
addit
marinederiv
compound
howev
found
use
biolog
probe
biochem
tool
studi
unusu
structur
andor
biolog
activ
includ
marinederiv
prostaglandin
palytoxin
ciguatoxin
brevetoxin
okada
acid
tetrodotoxin
saxitoxin
calyculin
kainic
acid
manoalid
also
sold
commerci
biochem
probe
chapter
hope
show
marin
natur
product
repres
promis
sourc
potenti
therapeut
agent
review
strategi
approach
academ
industri
lab
led
lead
discoveri
marin
natur
product
therapeut
potenti
highlight
sourc
biolog
activ
marin
natur
product
collect
techniqu
respect
sourc
organ
review
histori
statu
select
marinederiv
compound
variou
point
along
discoveri
develop
path
present
discuss
uniqu
difficulti
therapeut
develop
marinederiv
compound
chosen
focu
discuss
rel
low
molecular
weight
compound
deriv
primarili
marin
macroorgan
invertebr
alga
marin
microorgan
chosen
discuss
marinederiv
biopolym
ie
agglutinin
polysaccharid
glycoprotein
shimizu
kamiya
high
molecular
weight
toxin
ie
conotoxin
sea
anemon
polypeptid
toxin
jellyfish
toxin
marinederiv
neurotoxin
diagnost
reagent
marin
organ
exampl
horsesho
crab
cohen
compound
marin
vertebr
chapter
cover
literatur
approxim
middl
success
drug
discoveri
program
clearli
need
continu
sourc
new
compound
program
plan
continu
success
afford
exhaust
sourc
sampl
screen
may
consist
inhous
compound
librari
compound
variou
chemic
compani
univers
collect
natur
materi
acquisit
natur
materi
marin
environ
slow
develop
variou
reason
howev
situat
chang
dramat
past
year
first
step
discoveri
marinederiv
compound
therapeut
potenti
collect
marin
organ
marin
materi
microorgan
isol
pomponi
reed
pomponi
intens
systemat
collect
marin
organ
compound
therapeut
potenti
hamper
past
gener
lack
familiar
chemist
engag
research
marin
environ
lack
document
ethnonatur
histori
marin
organ
medicin
purpos
scheuer
appropri
collect
tool
techniqu
protocol
access
clinic
relev
assay
studi
marinederiv
compound
problem
larg
overcom
three
develop
greatli
aid
systemat
collect
marin
organ
compound
therapeut
potenti
includ
advent
scuba
year
ago
develop
deep
water
collect
tool
past
year
exampl
harbor
branch
oceanograph
institut
hboi
probabl
importantli
much
closer
collabor
among
scientist
varieti
disciplin
ie
marin
biologist
ecologist
chemic
ecologist
cell
biologist
biochemist
pharmacologist
natur
product
chemist
prior
scuba
shallow
water
sampl
could
obtain
wade
snorkel
collect
techniqu
limit
depth
feet
less
gener
ineffici
scuba
howev
allow
routin
collect
depth
feet
minut
bottom
time
decompress
stop
use
mixtur
nitrogen
oxygen
nitrox
helium
oxygen
instead
air
allow
scuba
collect
extend
durat
depth
miller
exampl
helium
oxygen
mixtur
may
allow
dive
feet
greater
nitrox
mixtur
nitrogen
may
doubl
bottom
time
depth
feet
mix
ga
dive
routin
howev
sampl
collector
mainli
profession
diver
use
gener
marin
organ
studi
date
collect
scuba
dive
deep
water
collect
made
dredg
trawl
costeffect
collect
method
substratum
caus
damag
snag
gear
sever
disadvantag
approach
difficult
photograph
organ
habitat
encrust
organ
organ
grow
crevic
ledg
steep
rock
face
easili
collect
unless
hard
substrat
support
organ
collect
well
dredg
trawl
put
collect
sampl
close
contact
therefor
organ
may
chemic
contamin
other
exud
secret
variou
compound
environment
impact
dredg
trawl
detriment
sampl
nonselect
habitat
damag
destroy
deep
water
collect
also
made
man
unman
submers
remot
oper
vehicl
rov
cost
form
collect
obvious
much
higher
dredg
trawl
approxim
doubl
tripl
howev
environment
impact
form
collect
neglig
rov
use
extens
oil
industri
survey
repair
oil
platform
marin
biologist
geologist
archeologist
survey
marin
biota
geolog
format
artifact
respect
howev
technolog
progress
suffici
render
rov
cost
effect
marin
sampl
collect
pomponi
person
commun
contrast
man
submers
exemplifi
hboi
locat
southeast
coast
florida
perform
well
select
pinpoint
collect
recollect
deep
water
marin
sampl
pharmacolog
evalu
hboijohnsonsealink
submers
exampl
accommod
total
four
passeng
oper
depth
feet
array
collect
devic
associ
sampl
storag
contain
facilit
collect
organ
display
wide
rang
shape
size
variou
video
mm
camera
purpos
document
use
man
submers
research
group
divis
biomed
marin
research
dbmr
hboi
exampl
collect
sampl
feet
galapago
island
variou
locat
caribbean
bahama
gulf
mexico
eastern
atlant
canari
madiera
island
collect
program
dbmr
hboi
collect
marin
macroorgan
consid
good
one
marin
field
collect
strategi
review
briefli
first
sever
year
research
effort
begin
strategi
collect
repres
mani
shallow
deep
water
benthic
organ
could
found
research
program
evolv
effort
began
focu
shallow
deep
water
spong
due
high
incid
biolog
activ
varieti
mechanismbas
whole
cell
assay
high
abund
especi
compar
organ
tunic
bryozoan
hydroid
special
tool
avail
collect
deep
water
sampl
import
nich
sampl
collect
effort
deep
water
spong
approxim
describ
speci
deep
water
environ
west
indian
biogeograph
region
van
soest
stentoft
dbmrhboi
collect
contain
nearli
collect
contain
least
anoth
new
undescrib
speci
deep
water
spong
comparison
total
number
describ
shallow
deep
water
speci
west
indian
biogeograph
region
approxim
pulitzerfinali
consequ
rather
enorm
collect
effort
current
dbmrhboi
collect
consist
total
sever
thousand
deep
water
well
shallow
water
macroorgan
sampl
suffici
quantiti
chemic
fraction
knowledg
largest
marin
sampl
collect
world
number
discret
sampl
uniqu
taxonomi
probabl
less
onethird
estim
base
taxonom
identif
genera
level
less
onequart
sampl
taxonom
identif
sampl
driven
biolog
activ
respect
extract
inact
sampl
identifi
unless
taxonom
identif
trivial
marin
research
group
success
focus
collect
drug
discoveri
effort
cnidaria
see
discuss
pseudopterosin
fuscosid
blue
green
alga
marinederiv
microorgan
gustafson
et
al
kobayashi
okami
microorgan
terrestri
environ
proven
sourc
antibiot
therapeut
agent
would
seem
like
microorgan
deriv
marin
environ
also
yield
therapeut
agent
howev
chemic
biolog
studi
slow
develop
faulkner
faulkner
gener
marinederiv
microorgan
isol
environment
sampl
ie
sediment
water
sampl
decay
piec
wood
etc
macroorgan
date
new
structur
found
marinederiv
bacteria
burkhold
et
al
gustafson
et
al
takahashi
et
al
umezawa
et
al
wratten
et
al
includ
actinomycet
nakamura
et
al
okami
et
al
sato
et
al
marinederiv
fungi
gloer
isol
techniqu
marinederiv
microorgan
rel
straightforward
exampl
obtain
microorgan
macroorgan
macroorgan
typic
rins
steril
seawat
blot
ground
artifici
seawat
filter
seawat
site
dilut
plate
onto
sever
differ
agar
media
wilkinson
sever
gener
sever
select
media
usual
use
primari
isol
cultur
exampl
gener
media
may
includ
zobel
marin
agar
zobel
peptoneyeast
extractseawat
weyland
actinomyceteselect
media
may
includ
starchyeast
extractseawat
chitinseawat
glycerolarginin
agarseawat
trace
metal
vitamin
ad
nonomura
ohara
well
cycloheximid
inhibit
fungal
growth
agar
cultur
incub
differ
temperatur
cultur
examin
period
coloni
transfer
appropri
media
purif
identif
biolog
chemic
studi
controversi
facet
marinederiv
microorgan
put
role
respect
origin
bioactiv
natur
product
marin
macroorganismmicroorgan
associ
ireland
et
al
symbiot
microorgan
repeatedli
suggest
direct
indirect
sourc
bioactiv
metabolit
marin
spong
frinck
faulkner
mccaffrey
endean
invertebr
ie
tunic
wright
et
al
bryozoan
fenic
symbiot
microorgan
broadest
work
definit
term
may
mutualist
parasit
associ
host
anim
symbiosi
may
obligatori
facult
isenberg
balow
actinomycet
ubiquit
marin
environ
goodfellow
hayn
weyland
marin
invertebr
contain
divers
commun
microorgan
bergquist
colwel
includ
actinomycet
e
armstrong
person
commun
cyanobacteria
wilkinson
sever
specif
exampl
exist
howev
secondari
metabolit
initi
extract
identifi
macroorgan
ie
spong
could
produc
ferment
specif
microorgan
strain
isol
respect
macroorgan
stierl
et
al
elyakov
et
al
noteworthi
case
regard
marin
vertebr
fishderiv
fatti
acid
seem
great
valu
prevent
cardiovascular
diseas
leaf
may
inde
produc
associ
marin
microorgan
kitagawa
et
al
natur
product
evidenc
numer
review
marin
natur
product
faulkner
faulkner
faulkner
faulkner
faulkner
faulkner
faulkner
shown
chapter
marin
environ
hous
vast
number
new
type
chemic
structur
mani
structur
repres
new
class
unknown
previous
natur
synthesi
analysi
review
indic
substanti
amount
research
conduct
chemist
europ
especi
itali
australia
new
zealand
israel
japan
north
america
greatest
number
marinederiv
compound
isol
shallow
water
organ
structur
publish
north
american
japanes
research
locat
academ
institut
knowledg
greater
number
academ
industri
research
group
becom
involv
past
sever
year
search
biolog
activ
novel
compound
marinederiv
microorgan
expect
increas
effort
reflect
scientif
patent
literatur
next
sever
year
collect
site
organ
contain
compound
span
globe
includ
caribbean
indopacif
mediterranean
red
sea
antarct
rel
deep
water
marin
organ
investig
although
appear
fertil
ground
biolog
activ
compound
shallow
deep
water
macroorgan
collect
tropic
subtrop
latitud
presum
milder
condit
sampl
collect
greater
biodivers
avail
organ
ricklef
factor
certainli
facilit
collect
greater
number
differ
organ
per
collect
effort
though
sampl
collect
higher
latitud
also
product
earlier
review
faulkner
show
phylet
distribut
marin
natur
product
report
ireland
et
al
time
period
marin
natur
product
deriv
alga
spong
cnidaria
echinoderm
tunic
bryozoan
microb
part
trend
relat
rel
abund
respect
organ
ie
tunic
bryozoan
hydroid
prolif
produc
structur
unusu
biolog
activ
natur
product
howev
anim
abund
alga
spong
cnidarian
echinoderm
respect
biosynthet
capabl
secondari
metabolit
alga
spong
cnidaria
produc
greater
proport
terpenoid
compound
type
three
group
organ
second
abund
biosynthet
class
compound
polyketid
analysi
compound
report
sinc
phylet
distribut
marin
natur
product
approxim
howev
total
number
compound
report
spong
report
alga
signific
increas
number
compound
report
tunic
marinederiv
microorgan
analys
review
emphas
biolog
activ
marin
natur
product
fusetani
kreb
munro
et
al
show
virtual
sessil
organ
repres
ie
spong
cnidarian
tunic
bryozoan
hydroid
zoanthid
microand
macroalga
therefor
although
experi
led
us
focu
effort
spong
believ
prematur
conclud
may
prefer
organ
activ
marinederiv
compound
particular
diseas
state
deep
water
macroorgan
marinederiv
microorgan
environ
organ
stress
environ
ie
hydrotherm
vent
anaerob
environ
etc
suffici
studi
case
search
continu
except
intens
systemat
bioassayguid
studi
extract
compound
marin
organ
academ
govern
industri
research
group
use
clinic
relev
assay
discov
natur
occur
substanc
therapeut
potenti
underway
less
year
tremend
advanc
understand
biolog
certain
diseas
concomit
explos
new
assay
research
posit
explor
fulli
potenti
marin
natur
product
biolog
advanc
highli
complement
develop
new
chemic
technolog
ie
new
separ
structur
elucid
techniqu
gener
drug
discoveri
strategi
trivial
separ
three
categori
chemic
driven
find
biolog
activ
purifi
compound
biolog
driven
bioassayguid
approach
begin
crude
extract
combin
chemic
biolog
driven
approach
vide
infra
marinederiv
drug
discoveri
strategi
may
involv
one
follow
element
vivo
screen
mechanismbas
screen
function
whole
cell
tissuebas
assay
onsit
assay
versu
postcollect
assay
derepl
via
biolog
profil
chemic
profil
eg
thin
layer
chromatographi
tlc
nuclear
magnet
reson
nmr
high
pressur
liquid
chromatographi
hplc
chemic
driven
tradit
grindandfind
approach
persino
pursu
vigor
primarili
academ
research
group
fact
major
academ
effort
studi
marin
natur
product
chemistri
driven
ie
object
search
novel
compound
marin
sourc
tlc
use
tlc
field
see
norri
fenic
h
nmr
dj
faulkner
person
commun
use
extens
screen
crude
extract
solvent
partit
unusu
therefor
interest
pattern
recent
c
nmr
use
mane
et
al
crew
et
al
adamezeski
et
al
structur
eleg
number
compound
found
variou
review
marin
natur
product
attest
success
approach
note
isol
structur
elucid
new
structur
complex
compound
provid
immens
gratif
marin
natur
product
chemist
inde
academ
synthet
chemist
thrive
new
synthet
challeng
respect
discov
potenti
therapeut
agent
chemic
driven
approach
viabl
one
marin
pharmacolog
program
univers
californiasanta
barbara
ucsb
scripp
institut
oceanographi
sio
fund
nearli
year
sea
grantnoaa
pure
compound
isol
primarili
laboratori
w
fenic
sio
dj
faulkner
sio
evalu
r
jacob
ucsb
although
mani
compound
isol
base
antibacteri
cytotox
andor
antiinflammatori
activ
respect
extract
mani
isol
base
pure
chemic
chemotaxonom
chemic
ecolog
interest
also
screen
r
jacob
jacob
et
al
antiinflammatori
properti
manoalid
see
section
exampl
discov
essenti
chemic
driven
process
contrast
antiinflammatori
properti
pseudopterosin
section
fuscosid
section
discov
activitydirect
effort
chemic
driven
approach
also
serv
valid
scientif
purpos
ie
structur
inform
use
help
solv
taxonom
problem
associ
varieti
marin
organ
bergquist
well
fenic
norri
lawson
et
al
liaaenjensen
et
al
pomponi
et
al
begin
today
major
academicbas
research
effort
becom
essenti
biolog
driven
ie
object
search
shift
discov
marinederiv
compound
biolog
activ
biolog
activ
includ
explor
potenti
agrochem
crawley
pharmaceut
well
possibl
chemic
ecolog
role
baku
et
al
hay
fenic
addit
marinederiv
compound
isol
structur
elucid
base
ethnonatur
histori
scheuer
compound
organ
implic
public
health
hazard
haddad
et
al
ie
tetrodotoxin
nakanishi
et
al
red
tide
shellfish
toxin
ciguatoxin
prime
exampl
screen
program
antitumor
agent
nci
biolog
driven
sinc
incept
suff
et
al
howev
major
us
academicbas
marin
natur
product
chemistri
group
fund
nci
grant
contract
basi
current
screen
program
util
extens
human
tumor
panel
includ
number
cell
line
repres
solid
tumor
differ
tissu
origin
clinic
respons
well
murin
human
leukemia
cell
line
approach
predic
assumpt
agent
identifi
exhibit
select
activ
toward
particular
tumor
histiotyp
select
detect
longterm
tissuecultureadapt
cell
line
johnson
hertzberg
numer
marinederiv
pure
compound
screen
panel
sever
compound
current
preclin
interest
lednic
person
commun
gener
comparison
drug
discoveri
industri
evolv
use
specif
assay
target
receptor
enzym
involv
pathogenesi
diseas
rather
cellular
tissu
assay
johnson
hertzberg
benefit
immens
breakthrough
receptor
technolog
hall
reuben
wittcoff
assay
reflect
new
opportun
due
recent
identif
previous
unrecogn
biomolecular
target
therapi
larson
fischer
specif
approach
diseas
area
character
industri
essenti
exclus
relianc
biolog
activ
crude
extract
numer
targetspecif
assay
ie
enzym
assay
receptorbind
assay
select
crude
extract
bioassayguid
fraction
crude
extract
priorit
criteria
emphas
select
potenc
high
volum
autom
screen
ie
thousand
sampl
per
year
smaller
compani
thousand
sampl
per
week
larger
compani
use
function
wholecel
assay
confirm
activ
particular
diseas
state
priorit
sampl
fraction
use
genet
engin
microorgan
enzym
receptor
exampl
target
approach
antitumor
area
includ
assay
multidrug
resist
revers
agent
mitogen
growth
factor
protein
tyrosin
kinas
antagonist
topoisomeras
inhibitor
dna
intercal
purinepyrimidin
nucleotid
biosynthesi
inhibitor
tubulin
polymer
inhibitor
signal
transduct
agonist
antagonist
phospholipas
phosphatidlyinositol
kinas
protein
kinas
c
assay
find
compound
interfer
express
function
oncogen
product
larson
fischer
johnson
hertzburg
one
major
pharmaceut
compani
reportedli
screen
everi
marineand
terrestri
deriv
extract
differ
assay
indic
area
cancer
aid
cardiovascular
inflammatori
diseas
persino
assay
priorit
one
provid
five
six
lead
structur
assay
drop
prioriti
lower
anoth
perhap
unproven
assay
brought
onlin
prioriti
anoth
assay
rais
antitumor
area
select
potenc
high
volum
screen
element
common
nci
industri
howev
nci
use
whole
cell
assay
industri
use
primarili
mechanismbas
assay
approach
appear
valid
case
nci
yet
disproven
argument
put
forth
support
use
either
approach
argument
use
mechanismofact
screen
primari
screen
serendip
pharmacolog
lack
use
activ
may
miss
suff
et
al
argument
wholecel
system
gener
pharmacokinet
problem
address
compound
ca
nt
cross
membran
test
neg
also
metabol
activ
requir
activ
chanc
occur
wholecel
system
area
immun
modul
whole
cell
assay
eg
mix
lymphocyt
reaction
mlr
mitogen
respons
lymphokin
product
assay
rather
receptor
enzym
assay
continu
use
routin
academ
govern
industri
research
group
least
antitumor
area
argument
use
whole
cell
cytotox
assay
uneconom
unproduct
requir
discrimin
bona
fide
lead
therapeut
potenti
vast
number
known
cytotox
natur
product
larg
number
cell
line
extract
must
test
overwhelm
major
cytotox
natur
product
minim
signific
activ
certain
chemosensit
anim
tumor
model
johnson
hertzberg
addit
practic
concern
often
face
pharmaceut
compani
decid
compound
develop
whether
mechan
ofact
known
ie
known
visavi
mechanismbas
screen
effort
substanti
effort
requir
determin
mode
action
determin
compound
likelihood
pursu
hecht
person
commun
low
correl
cytotox
antitumor
activ
number
program
util
vivo
tumor
model
directli
drug
discoveri
johnson
hertzberg
nci
use
vivo
murin
leukemia
assay
primari
screen
suff
et
al
boyd
et
al
success
primarili
identifi
compound
possess
clinic
activ
leukemia
lymphoma
unfortun
success
find
compound
activ
slow
grow
tumor
human
vivo
assay
expens
time
consum
rel
insensit
suff
et
al
experi
hboi
diseas
area
shown
activ
vitro
antivir
assay
translat
well
vivo
activ
eg
use
herp
simplex
contrast
reason
correl
exist
vitro
vivo
antifung
activ
eg
use
candida
albican
vitro
vivo
immun
suppress
activ
eg
use
mlr
vitro
assay
graftversushost
reaction
gvhr
splenomegali
model
follow
vivo
assay
chemic
biolog
driven
approach
combin
experi
combin
approach
meant
select
extract
chemic
fraction
base
biolog
activ
profil
crude
extract
howev
instead
use
bioassayguid
approach
purifi
compound
respons
activ
extract
nmr
tlc
use
isol
chemic
interest
substanc
ideal
structur
unusu
novel
compound
also
respons
activ
extract
approach
work
well
activ
compound
present
high
concentr
assay
turnaround
time
longer
coupl
week
concentr
low
case
ecteinascidin
wright
et
al
structur
complex
isoquinolin
alkaloid
found
level
mg
kg
tunic
ecteinascidia
turbinata
activ
compound
would
overlook
complet
pure
chemic
approach
employ
approach
inde
product
respect
isol
numer
new
compound
least
usual
express
activ
observ
crude
extract
obvious
best
method
identifi
activ
compound
present
low
concentr
element
biolog
driven
approach
use
research
group
onsit
shipboard
assay
rinehart
rinehart
rinehart
shield
propon
onsit
bioassay
point
recollect
organ
whose
extract
found
activ
made
immedi
organ
whose
extract
prove
inact
collect
trip
subsequ
avoid
chanc
improv
observ
biolog
activ
extractssampl
may
undergo
degrad
enzym
air
heat
requir
onsit
bioassay
consum
much
time
simpl
rug
involv
pathogen
organ
argument
use
onsit
bioassay
includ
follow
sampl
collect
expens
activ
especi
larg
research
vessel
associ
submers
therefor
effici
product
plan
focu
effort
collect
fill
ship
berth
expert
sampl
collect
organ
identif
rather
expert
conduct
assay
optimum
collect
strategi
collect
sampl
mani
differ
local
habitat
possibl
chart
cours
collect
trip
gener
involv
retrac
part
rout
therefor
practic
count
recollect
larger
amount
particular
organ
whose
extract
exhibit
activ
assay
take
sever
day
wait
one
collect
site
vicin
assay
result
evalu
wast
collect
resourc
valid
strategi
optim
find
new
marinederiv
compound
therapeut
potenti
respect
extract
evalu
mani
clinic
relev
assay
possibl
make
collect
decis
simpl
usual
unsophist
rug
onsit
assay
impos
unnecessari
constraint
worri
sampl
degrad
take
reason
precaut
eg
freez
sampl
store
solvent
biolog
evalu
also
impos
unnecessari
constraint
experi
biolog
activ
frozen
sampl
remain
intact
year
simpli
worth
effort
concern
oneself
minor
sampl
somewhat
labil
import
element
chemic
biolog
driven
approach
derepl
defin
elimin
replic
repeat
materi
alreadi
isol
known
literatur
suff
et
al
technic
resourc
inc
biolog
driven
approach
concept
simpli
determin
quickli
possibl
chemic
natur
compound
respons
biolog
activ
crude
extract
inform
hand
inform
decis
made
whether
expend
preciou
resourc
bioassayguid
isol
structur
elucid
activ
compound
numer
databas
avail
assist
derepl
technic
resourc
inc
includ
assembl
j
berdi
institut
drug
research
budapest
hungari
j
french
warner
lambert
pharmaceut
compani
dj
faulkner
sio
n
apr
alert
natur
product
alert
literatur
databas
assembl
nr
farnsworth
univers
illinoi
chicago
chemic
abstract
databas
assembl
initi
p
crew
univers
californiasanta
cruz
crew
et
al
embellish
group
dbmrhboi
research
marin
natur
product
field
hand
derepl
marinederiv
compound
macroorgan
consist
taxonomi
chemic
analysi
biolog
profil
approach
first
use
biolog
activ
profil
extract
order
decid
whether
continu
effort
sampl
decis
affirm
solvent
partit
extract
prepar
biolog
activ
profil
obtain
organ
aqueou
layer
solvent
partit
activ
persist
one
solvent
partit
taxonomi
sourc
organ
ascertain
hboi
expert
spong
gorgonian
algal
taxonomi
collabor
whose
taxonom
expertis
cover
phyla
concurr
nmr
spectra
tlc
data
obtain
crude
extract
solvent
partit
base
data
biolog
activ
profil
crude
extract
solvent
partit
sever
databas
consult
better
understand
natur
compound
may
respons
biolog
activ
sourc
organ
year
biolog
activ
taxonomi
data
marin
organ
databas
assembl
dj
faulkner
sio
inform
retriev
organ
type
name
research
compound
name
genu
speci
name
molecular
formula
molecular
weight
databas
assembl
p
crew
chemic
abstract
crew
databas
search
combin
structuresubstructur
number
carbon
hydrogen
molecul
socal
attach
proton
test
apt
formula
molecular
weight
taxonomi
known
respect
variou
approach
use
isol
marin
natur
product
therapeut
potenti
somewhat
obviou
truism
put
forthon
usual
find
one
look
novel
compound
sought
chemic
driven
approach
may
subsequ
evalu
biolog
activ
nmr
tlc
hplc
andor
liquid
chromatographymass
spectrometri
lcm
use
screen
extract
taxonom
identif
respect
organ
use
well
derepl
biolog
activ
compound
sought
biolog
driven
approach
mechanismbas
function
whole
cell
tissuebas
vivo
assay
use
screen
extract
guid
chemic
fraction
regard
marin
natur
product
biolog
driven
approach
appropri
mani
compound
whose
structur
publish
thoroughli
evalu
biolog
activ
well
appreci
new
assay
redefin
otherwis
exhaust
compound
extract
librari
whole
new
sampl
set
particular
biolog
driven
approach
critic
howev
marinederiv
compound
sought
therapeut
potenti
inde
discrimin
predict
assay
requir
find
compound
use
therapeut
within
next
year
rather
year
optim
biolog
driven
approach
interorganiz
collabor
group
expertis
chemistri
biolog
research
develop
import
view
academ
govern
industri
research
group
truli
resourc
expertis
interest
complet
autonom
take
compound
ocean
market
academ
govern
research
group
typic
expertis
readi
access
expertis
marin
biolog
ecolog
sampl
collect
procur
sometim
ferment
isol
structur
elucid
synthesi
usual
biolog
evalu
limit
number
diseas
area
mani
industri
concern
usual
expertis
isol
structur
elucid
synthesi
biolog
evalu
process
chemistri
ferment
preclin
clinic
develop
patent
market
pharmaceut
compani
howev
view
natur
product
one
sourc
drug
discoveri
program
therefor
resourc
spread
natur
product
screen
chemic
synthesi
experi
best
relationship
strive
academ
industri
program
scientif
collabor
ie
one
extens
exchang
technic
inform
take
place
academ
point
view
need
usual
modest
ie
scientif
gratif
monetari
support
research
industri
point
view
sampl
obtain
inform
exchang
collabor
must
ultim
commerci
benefit
order
stay
busi
relat
industri
concern
confidenti
unfortun
best
fit
academ
goal
publish
perish
distinct
advantag
work
pharmaceut
compani
possibl
marinederiv
compound
express
suitabl
profil
compani
point
view
resourc
expertis
conduct
structureact
optim
studi
may
becom
avail
studi
compound
suppli
suffici
quantiti
optim
compound
ferment
synthesi
preclin
clinic
studi
typic
academ
group
simpli
posit
accomplish
task
goal
marinederiv
drug
becom
realiti
sort
appropri
partnership
academ
group
interest
develop
partner
necessari
inevit
last
year
sever
marinederiv
compound
gener
consider
interest
scientif
commerci
public
health
point
view
includ
prostaglandin
potent
structur
complex
toxin
palytoxin
one
major
caus
agent
fish
poison
ciguatoxin
uniqu
potent
biolog
activ
sever
marinederiv
compound
alreadi
found
use
biolog
probe
biochem
tool
sold
commerci
ie
palytoxin
brevetoxin
eg
brevetoxin
okada
acid
tetrodotoxin
saxitoxin
calyculin
manoalid
kainic
acid
prostaglandin
group
monocycl
fatti
acid
metabolit
possess
divers
potent
biolog
activ
includ
control
blood
pressur
renal
blood
flow
smooth
muscl
contract
gastric
acid
secret
involv
inflamm
berkow
flethcher
caribbean
gorgonian
plexaura
homomalla
anim
relat
sea
fan
sea
whip
report
contain
larg
concentr
diester
weinheim
spraggin
unfortun
configur
render
compound
physiolog
inact
howev
limit
suppli
mammalian
prostaglandin
sheep
semin
tissu
time
great
interest
p
homomalla
potenti
commercialscal
sourc
synthet
precursor
weinheim
spraggin
corey
matsuda
determin
p
homomalla
grew
well
shallow
depth
caribbean
artifici
substrat
corey
matsuda
subsequ
industri
process
chemistri
synthes
activ
prostaglandin
improv
interest
wane
harvest
p
homomalla
ocean
scientif
viewpoint
p
homomalla
continu
gener
interest
prostaglandin
found
anim
soft
coral
ie
clavulon
eg
clavulon
found
clavularia
viridi
kikuchi
et
al
produc
mammalian
cyclooxygenaseendoperoxid
rout
corey
et
al
rather
appear
produc
arachidon
acid
hpoxygen
subsequ
transform
allen
oxid
follow
oxidopentadienyl
cation
intermedi
intermedi
readili
account
observ
well
cyclopropyl
compound
produc
arachidon
acid
incub
aceton
powder
p
homomalla
corey
matsuda
baertshi
et
al
addit
physiolog
inact
pga
methyl
ester
clavulon
marinederiv
prostanoid
subsequ
report
p
homomalla
includ
physiolog
activ
pga
pge
acet
methyl
ester
bundi
et
al
schneider
et
al
schneider
et
al
schneider
et
al
pgf
gorgonean
euplexaura
erecta
komoda
et
al
pge
pgf
red
alga
gracilaria
lichenoid
gregson
et
al
pgf
methyl
ester
deriv
well
two
correspond
free
carboxyl
acid
soft
coral
lobophyton
depressum
carm
et
al
claviridenon
eg
claviridenonea
c
viridi
kobayashi
et
al
chlorovulon
eg
chlorovulon
c
viridi
iguchi
et
al
punaglandin
eg
punaglandin
octocor
telesto
riisei
baker
et
al
sever
pge
pge
pge
isol
first
time
natur
sourc
nudibranch
mollusk
tethi
fimbria
cimino
et
al
oac
punaglandin
analog
report
express
cytotox
ic
ngml
baker
et
al
chlorovolun
report
cytotox
human
promyelocyt
leukemia
cell
ic
iguchi
et
al
clavulon
show
antiinflammatori
effect
fertil
egg
assay
use
chorioallanto
membran
chick
embryo
site
induc
inflamm
kikuchi
et
al
kikuchi
et
al
independ
structur
elucid
palytoxin
uemura
et
al
subsequ
complet
structur
determin
compound
stereochemistri
synthesi
palytoxin
carboxyl
acid
kishi
research
group
armstrong
et
al
armstrong
et
al
refer
therein
must
consid
quintessenti
scientif
achiev
pali
toxin
larg
polyoxygen
metabolit
molecular
weight
obtain
zoanthid
palythoa
toxica
palythoa
speci
pose
extrem
challeng
structur
elucid
achiev
oxid
degrad
molecul
elucid
degrad
product
larger
mani
natur
product
biolog
activ
viewpoint
especi
noteworthi
potent
nonproteinac
toxin
known
minimum
lethal
dose
guinea
pig
haddad
et
al
comparison
potent
proteinac
toxin
botulinu
toxin
minimum
lethal
dose
twostag
mous
skin
promot
assay
pali
toxin
also
potent
tumor
promot
although
fail
induc
ornithin
decarboxylas
mous
skin
bind
protein
kinas
c
fujicki
et
al
similar
phorbol
estertyp
tumor
promot
palytoxin
found
stimul
arachidon
acid
metabol
rat
liver
cell
levin
fujicki
palytoxin
also
act
synergist
phorbol
estertyp
tumor
promot
promot
prostaglandin
releas
levin
fujicki
levin
et
al
stimul
histamin
releas
rat
periton
mast
cell
ouchi
et
al
palytoxin
found
inhibit
epiderm
growth
factor
egf
bind
pathway
depend
upon
protein
kinas
c
wattenberg
et
al
palytoxin
commerci
avail
ciguatoxin
primari
caus
agent
ciguatera
type
food
poison
occur
intermitt
unpredict
eat
certain
coral
reef
fish
haddad
et
al
murata
et
al
yasumoto
murata
characterist
clinic
syndrom
includ
sever
gastrointestin
neurolog
symptom
haddad
et
al
affect
annual
approxim
peopl
worldwid
although
origin
ciguatoxin
subject
specul
centuri
haddad
et
al
caus
organ
dinoflagel
gambierdiscu
toxicu
identifi
yasumoto
et
al
ciguatoxin
transfer
food
chain
among
coral
reef
biota
accumul
carnivor
fish
includ
barracuda
grouper
amberjack
dolphinfish
pompono
morey
eel
other
although
research
isol
structur
elucid
ongo
sinc
scheuer
et
al
toxin
alway
present
trace
quantiti
affect
fish
structur
final
solv
recent
less
mg
kg
moray
eel
viscera
use
primarili
nmr
structur
determin
polyeth
structur
similar
polyeth
toxin
dinoflagel
brevetoxin
vide
infra
numer
marinederiv
compound
addit
palytoxin
commerci
avail
brief
descript
substanc
sourc
biolog
activ
util
compound
follow
dinoflagel
toxin
eg
brevetoxin
shimizu
et
al
express
toxic
sitespecif
bind
associ
voltagesensit
sodium
channel
caus
contractil
paralysi
anim
model
trainer
et
al
dinoflagel
toxin
murata
et
al
first
isol
spong
tachibana
et
al
implic
major
caus
agent
diarrhet
shellfish
poison
potent
tumor
promot
activ
protein
kinas
c
potent
inhibitor
protein
toxin
express
mark
contractil
effect
smooth
muscl
heart
muscl
haystead
et
al
bacteri
metabolit
tamplin
also
found
fish
pufferfish
starfish
crab
octopu
frog
newt
salamand
gobi
gastropod
mollusk
flatworm
annelid
zooplankton
alga
nakanishi
et
al
potent
toxin
revers
block
sodium
channel
effect
potassium
channel
blockag
use
marker
sodium
channel
excit
tissu
use
block
sodium
channel
multipl
conduct
system
studi
calcium
channel
cardiac
muscl
hu
kao
bacteri
metabolitedinoflagel
toxin
tamplin
one
main
caus
agent
paralyt
shellfish
poison
potent
revers
channel
block
agent
similar
mechanismofact
tetrodotoxin
kio
spong
metabolit
kato
et
al
matsunaga
fusetani
inhibit
protein
phosphatas
also
serv
okada
acid
receptor
promot
tumor
growth
cdi
mous
skin
induc
ornithin
decarboxylas
mous
skin
suganuma
et
al
also
exhibit
antitumor
activ
ehrlich
leukemia
mice
kato
et
al
kato
et
al
compound
spong
metabolit
inhibit
phospholipas
c
interven
arachidon
acid
cascad
wheeler
et
al
see
section
red
algal
metabolit
wellknown
anthelmint
fattorusso
piatelli
excitatori
amino
acid
affect
mammalian
amphibian
central
nervou
system
use
neurobiolog
tool
studi
huntington
diseas
epilepsi
mcgeer
et
al
serv
research
tool
marinederiv
compound
import
spinoff
effect
facilit
discoveri
therapeut
agent
exampl
role
found
case
marin
neurotoxin
tetrodotoxin
saxitoxin
compound
specif
distinct
action
function
voltagesensit
sodium
channel
excit
tissu
year
serv
probe
investig
structur
function
sodium
channel
protein
role
overal
function
neuromuscular
tissu
studi
lead
identif
new
biochem
target
chemic
intervent
thu
facilit
new
drug
discoveri
marinederiv
compound
studi
biolog
beyond
simpl
assess
cytotox
antimicrobi
activ
therefor
difficult
fulli
assess
therapeut
potenti
purpos
section
share
histori
result
indepth
biolog
studi
sever
marinederiv
compound
therapeut
potenti
dercitin
express
antitumor
activ
mycalamid
b
structur
relat
compound
onnamid
also
exhibit
antitumor
activ
well
antivir
activ
discodermolid
microcolin
b
display
promis
immunosuppress
activ
fuscosid
promis
antiinflammatori
agent
compound
deriv
varieti
sessil
shallow
deep
water
marin
organ
spong
gorgonian
blue
green
alga
collect
throughout
world
compound
synthes
dercitin
one
mani
acridin
heterocycl
isol
identifi
last
year
ascidian
collect
indopacif
red
sea
shallow
deep
water
spong
collect
indopacif
caribbean
dercitin
isol
deep
water
caribbean
spong
dercitu
sp
gunawardana
et
al
structur
relat
compound
includ
nordercitin
dercitamin
dercitamid
kuanoniamin
c
carrol
scheuer
cyclodercitin
dehydrocyclodercitin
stellettamin
gunawardana
et
al
dercitin
isol
use
bioassayguid
approach
dercitu
sp
spong
select
antitumor
lead
base
vitro
vivo
activ
crude
extract
ie
inhibit
vitro
cell
prolifer
percent
treatment
control
tc
mgkg
intraperiton
ip
purif
dercitin
achiev
follow
vitro
activ
concentr
dercitin
dercitu
sp
high
approxim
wet
weight
ie
g
compound
obtain
g
frozen
spong
howev
spong
difficult
collect
pomponi
person
commun
spong
encrust
mean
requir
substanti
effort
scrape
rock
resid
deep
water
mean
collect
submers
possibl
collect
encrust
spong
trawl
dredg
vitro
biolog
profil
dercitin
found
tabl
gunawardana
et
al
cross
p
mccarthi
unpublish
data
dercitin
time
activ
vitro
congen
nordercitin
ic
dercitamin
ic
dercitamid
ic
cyclodercitin
ic
dehydrocyclodercitin
ic
stelletamin
ic
antitumor
properti
mechanismofact
dercitin
studi
dercitin
prolong
life
micebear
ascit
tumor
tc
mgkg
ip
activ
ip
melanoma
tc
mgkg
ip
modestli
inhibit
growth
subcutan
sc
lewi
lung
carcinoma
median
tumor
volumeuntr
tumor
volum
mgkg
ip
fusedr
acridin
structur
dercitin
suggest
possibl
intercal
exogen
calf
thymu
dna
mg
ml
found
protect
cell
expos
dercitin
concentr
incorpor
studi
dercitin
disrupt
dna
rna
synthesi
wherea
effect
protein
synthesi
less
pronounc
profil
similar
known
intercal
actinomycin
daunomycin
addit
either
calf
thymu
dna
calf
liver
rna
solut
dercitin
alter
visibl
spectrum
dercitin
manner
consist
bind
equilibrium
dialysi
experi
reveal
dercitin
bind
calf
thymu
dna
satur
affin
maxim
bind
mol
dercitin
base
pair
dercitin
found
relax
coval
close
supercoil
dna
concentr
nm
requir
halfmaxim
relax
relax
revers
dna
intercal
dercitin
found
relat
affect
topoisomeras
ii
dercitin
complet
inhibit
dna
polymeras
idnas
nick
translat
howev
effect
dercitin
enzym
activ
appear
secondari
chang
dna
conform
discodermolid
new
polyhydroxyl
lacton
shallow
water
caribbean
spong
discodermia
dissoluta
express
immun
suppress
activ
gunasekera
et
al
spong
discodermia
speci
collect
caribbean
water
adjac
okinawa
proven
prolif
produc
structur
divers
biolog
activ
compound
includ
discodermin
matsunaga
et
al
matsunaga
et
al
cyclic
polypeptid
contain
residu
calyculin
eg
calyculin
section
discodermid
gunasekera
et
al
polydiscamid
gulavita
et
al
discodermindol
sun
sakemi
discodermin
cytotox
exhibit
antimicrobi
activ
calyculin
potent
cytotoxin
recent
found
protein
phosphatas
inhibitor
discodermid
express
antifung
ac
tiviti
relat
structur
antimicrobi
agent
ikarugamycin
isol
streptomyc
phaeochromogen
var
ikaruganensi
sakai
ito
hirata
jomon
et
al
polydiscamid
exhibit
vitro
cytotox
murin
leukemia
human
lung
cancer
gulavita
et
al
discodermindol
also
express
cytotox
structur
type
divers
discodermia
metabolit
argu
involv
microorgan
associ
spong
effort
underway
hboi
isol
microorgan
produc
relat
compound
armstrong
et
al
dissoluta
select
lead
base
initi
antifung
properti
crude
alcohol
extract
c
albican
crude
extract
also
express
cytotox
modest
immun
suppress
activ
howev
cytotox
properti
releg
extract
lower
prioriti
immunosuppress
lead
although
vitro
c
albican
activ
follow
fraction
also
test
mlr
assay
cytotox
fraction
also
exhibit
potent
immunosuppress
activ
ultim
discodermolid
isol
fraction
consequ
discodermolid
found
inhibit
vitro
prolifer
cultur
murin
leukemia
cell
ic
suppress
twoway
mix
lymphocyt
respons
murin
splenocyt
human
peripher
blood
lymphocyt
respect
importantli
immunosuppress
activ
accompani
greater
viabil
splenocyt
cell
concentr
gunasekera
et
al
discodermid
found
respons
antifung
activ
dissoluta
extract
c
albican
minimum
inhibitori
concentr
mic
polydiscamid
isol
differ
possibl
new
deep
water
speci
discodermia
isol
simpli
high
concentr
water
partit
waterbutanol
solvent
partit
ethanol
extract
biolog
activ
subsequ
discov
ic
human
lung
cancer
ic
discodermindol
isol
polydiscu
express
cytotox
ic
human
colon
cancer
ic
quantit
studi
discodermolid
longley
et
al
reveal
potent
suppress
murin
twoway
mlr
concanavalin
con
stimul
splenocyt
cultur
ic
valu
respect
valu
approxim
less
potent
commonli
report
suppress
murin
mlr
respons
immunosuppress
standard
cyclosporin
csa
evid
cytotox
murin
splenocyt
discodermolid
concentr
high
discodermolid
also
activ
suppress
twoway
mlr
human
peripher
blood
lymphocyt
pbl
ic
con
ic
phytohemagglutinin
pha
ic
stimul
pbl
discodermolid
cytotox
human
pbl
concentr
high
comparison
standard
immunosuppress
agent
csa
discodermolid
equal
effect
inhibit
tcell
receptor
tcr
accessori
cell
independ
calcium
depend
pmaionomycin
induc
prolifer
purifi
murin
tlymphocyt
ic
valu
nm
discodermolid
csa
find
suggest
discodermolid
suppress
activ
reach
beyond
tcell
activ
via
inhibit
tcr
mediat
activ
interfer
celltocel
interact
bcell
macrophag
discodermolid
significantli
suppress
product
pmaionomycin
stimul
murin
splenocyt
howev
express
associ
receptor
measur
fluoresc
microscopi
flow
cy
tome
trie
analys
use
antibodi
cell
reduc
similar
result
obtain
phastimul
blast
cell
obtain
human
pbl
express
tac
antigen
human
receptor
evalu
receptor
mous
human
normal
low
affin
bind
malek
et
al
waldman
howev
chain
associ
addit
cell
surfac
kda
protein
form
receptor
high
affin
appar
uniqu
mechan
action
ascrib
discodermolid
would
great
interest
determin
suppress
extend
high
affin
complex
addit
wherea
discodermolid
suppress
pmaionomycin
stimul
murin
tcell
examin
microscop
cell
appear
alreadi
undergon
blast
transform
indic
activ
alreadi
taken
place
longley
et
al
discodermolid
mechan
action
may
resembl
rapamycin
rather
csa
metcalf
richard
blockag
may
occur
g
rather
gqgx
interfac
csa
final
discodermolid
appear
inhibit
protein
synthesi
per
se
indic
methionin
incorpor
studi
longley
unpublish
observ
precis
vitro
mechan
action
discodermolid
still
remain
elucid
vivo
activ
discodermolid
also
studi
longley
et
al
compound
evalu
gvhr
splenomegali
assay
use
balbc
cbofj
balbc
x
f
model
initi
experi
discodermolid
effect
suppress
gvhr
allogen
graft
mice
mgkg
administ
daili
ip
inject
day
two
higher
dosag
result
greatest
suppress
respons
respect
dosag
associ
degre
morbid
group
two
five
four
five
survivor
respect
howev
lower
dosag
group
mgkg
continu
exhibit
substanti
suppress
respons
associ
morbid
mice
similarli
treat
mgkg
csa
exhibit
suppress
splenomegali
respons
order
determin
endpoint
vivo
immunosuppress
action
discodermolid
second
doserang
experi
initi
mice
treat
mgkg
discodermolid
suppress
gvhr
dosag
test
morbid
associ
mgkg
group
howev
remain
group
exhibit
suppress
respons
group
continu
express
suppress
comparison
csatreat
allogen
graft
mice
demonstr
suppress
endpoint
suppress
discodermolid
yet
determin
splenocyt
obtain
discodermolidetr
allogen
graft
mice
suppress
respons
con
abil
lyse
tumor
cell
natur
killer
cell
assay
compar
vehicletr
allogen
graft
control
longley
et
al
product
con
suppress
highest
discodermolid
dosag
group
mgkg
contrast
suppress
csa
discodermolid
also
evalu
vivo
effect
primari
serum
antibodi
respons
tdepend
antigen
sheep
red
blood
cell
srbc
mice
treat
daili
ip
inject
mgkg
discodermolid
mg
kg
csa
compar
standard
rather
surpris
result
discodermolid
suppress
srbc
antibodi
respons
even
highest
dosag
contrast
csatreat
mice
suppress
abil
mount
respons
result
consist
known
mechan
action
csa
result
indic
immunosuppress
effect
discodermolid
appear
gener
natur
fact
seem
uniqu
result
collect
indic
vivo
mechan
action
discodermolid
differ
csa
fact
may
indic
entir
novel
mechan
immunosuppress
effect
endpoint
suppress
vivo
gvhr
yet
reach
howev
conserv
estim
discodermolid
vivo
comparison
csa
via
ip
rout
indic
compound
time
potent
vivo
compar
csa
work
regard
discodermolid
appar
uniqu
vivo
mechan
action
evalu
addit
vivo
model
graft
reject
current
underway
fuscosid
b
diterpenoid
arabinos
glycosid
isol
caribbean
gorgonian
eunicea
fusca
shin
fenic
collabor
sea
grantnoaafund
research
group
sio
ucsb
fuscosid
one
major
compon
extract
found
reduc
phorbol
ester
pma
induc
mous
ear
edema
compar
indomethacin
wherea
fuscosid
b
slightli
less
activ
jacobson
jacob
howev
fuscosid
b
appear
select
inhibit
leukotrien
synthesi
ie
block
product
ltc
murin
macrophag
activ
calcium
ionophor
effect
product
pge
antiinflammatori
effect
fuscosid
long
last
found
activ
human
neutrophil
studi
well
jacobsen
jacob
microcolin
b
lipopeptid
filament
blue
green
alga
lyngbya
majuscula
microcoleu
lyngbyac
exhibit
potent
immunosuppress
activ
sampl
contain
compound
collect
southern
caribbean
coast
venezuela
sampl
recent
collect
near
miami
also
contain
suit
lipopeptid
metabolit
lyngbya
majuscula
notabl
appear
exist
multipl
chemic
distinct
varieti
exampl
one
shallow
water
strain
caus
swimmer
itch
contact
dermat
caus
lyngbyatoxin
cardellina
et
al
aimi
et
al
aplysiatoxin
shallow
water
sampl
l
majuscula
also
contain
epimer
lipopeptid
majusculamid
b
marner
et
al
wherea
deep
water
varieti
contain
antifung
cyclic
depsipeptid
majusculamid
c
carter
et
al
normajusculamid
c
mynders
et
al
deep
water
sampl
l
majuscula
also
furnish
two
cytotox
lipopeptid
majusculamid
deoxymajusculamid
moor
entzeroth
share
structur
similar
microcolin
b
sinc
contain
tyrosin
instead
nmethyl
leucin
crude
ethanol
extract
alga
show
vitro
activ
murin
leukemia
ic
immunosuppress
activ
mlr
howev
extract
express
lymphotox
lymphocyt
viabil
assay
lcv
lymphotox
bioassayguid
purif
undertaken
use
cytotox
primari
indic
later
semipur
chromatographi
fraction
contain
microcolin
b
subsequ
evalu
mlr
lcv
assay
nontox
dose
impress
immunosuppress
properti
recogn
vitro
biolog
profil
compound
present
tabl
experi
wherebi
purifi
tlymphocyt
induc
prolifer
combin
action
calcium
ionophyor
ionomycin
phorbol
ester
pma
microcolin
yield
ec
valu
nm
cyclosporin
yield
ec
nm
experi
experiment
result
suggest
appar
mechan
action
microcolin
may
directli
involv
tlymphocyt
relat
suppress
action
mlr
experi
longley
koehn
studi
effect
microcolin
product
receptor
express
con
astimul
splenocyt
indic
mechan
microcolin
suppress
action
involv
modul
product
receptor
express
per
se
sever
vivo
experi
longley
et
al
use
simonsen
gvhr
splenomegali
model
microcolin
mgkg
suppress
splenomegali
respons
higher
dosag
regimen
mgkg
result
death
anim
dose
lower
mgkg
associ
suppress
splenic
respons
howev
suppress
respons
splenocyt
obtain
two
lower
dosag
group
mg
kg
observ
pha
con
stimul
indic
specif
cell
subset
possibl
bcell
macrophag
affect
vivo
mycalamid
b
polyoxygen
compound
new
zealand
shallow
water
spong
mycal
sp
perri
et
al
perri
et
al
exhibit
variou
type
biolog
activ
includ
vivo
antitumor
activ
wide
varieti
tumor
model
antivir
activ
spong
mycal
sp
collect
research
group
univers
canterburi
collabor
effort
group
research
group
hboi
crude
spong
extract
exhibit
potent
cytotox
vitro
antivir
activ
assay
conduct
univers
canterburi
use
bioassayguid
approach
mycalamid
b
purifi
shown
respons
biolog
activ
extract
perri
et
al
interestingli
mycalamid
resembl
pederin
relat
compound
isol
terrestri
beetl
paederu
fuscip
see
refer
perri
et
al
och
concurr
independ
investig
shallow
water
okinawan
spong
theonella
sp
harbor
branch
oceanograph
institut
research
group
univers
ryuku
sakemi
et
al
structur
relat
compound
onnamid
isol
use
combin
chemic
biolog
driven
approach
och
mycalamid
onnamid
express
potent
cytotox
shown
tabl
three
compound
highli
cytotox
toward
howev
compar
mycalamid
b
onnamid
found
less
cytotox
human
promyelocyt
leukemia
cell
line
human
colon
cancer
cell
line
human
lung
cancer
cell
line
none
compound
induc
cell
differenti
mycalamid
b
found
exhibit
similar
vivo
efficaci
ip
murin
leukemia
model
best
respons
mycalamid
b
tc
respect
wherea
onnamid
found
virtual
inact
best
respons
tc
presum
ion
adapt
permiss
murin
leukemia
human
leukemia
human
colon
cancer
human
lung
cancer
izabl
arginin
group
molecul
may
result
poor
uptak
passag
across
membran
three
compound
express
efficaci
ip
reticulum
cell
sarcoma
model
best
respons
mycalamid
b
onnamid
tc
ip
ip
ip
respect
vivo
evalu
mycalamid
found
substanti
activ
solid
tumor
murin
human
origin
murin
leukemia
tabl
experi
aim
toward
elucid
cytotox
mechan
action
mycalamid
b
onnamid
three
compound
found
markedli
inhibit
protein
dna
synthesi
cell
intermedi
effect
rna
synthesi
mycalamid
b
found
potent
protein
synthesi
inhibitor
onnamid
least
potent
three
compound
found
inhibit
translat
cellfre
extract
use
brome
mosaic
viru
rna
substrat
lyse
rabbit
reticulocyt
mycalamid
b
found
potent
mycalamid
found
least
potent
experi
determin
whether
mycalamid
intercal
dna
mycalamid
found
alter
neither
electrophoret
mobil
supercoil
dna
lose
antiprolif
effect
combin
thymidin
deoxycytidin
deoxyadenosin
deoxyguanosin
biolog
evalu
mycalamid
antivir
antimicrobi
assay
reveal
express
antivir
activ
exhibit
antibacteri
activ
perri
et
al
cross
p
mccarthi
unpublish
observ
mycalamid
exhibit
vitro
antivir
activ
tabl
herp
simplex
type
vesicular
stomat
polio
vaccin
type
coronaviru
hiv
latter
assess
carri
ncinih
vivo
activ
observ
murin
coronaviru
mycalamid
onnamid
synthes
kishi
structur
biolog
activ
sever
marinederiv
compouhd
current
clinic
trial
includ
bryostatin
didemnin
b
manoalid
pseudopterosin
includ
e
present
follow
section
bryostatin
seri
structur
relat
macrocycl
lacton
deriv
bryozoan
bugula
neritina
studi
antitumor
immunomodulatori
properti
year
gr
pettit
research
group
univers
arizona
scientist
nci
collabor
histori
bryostatin
research
previous
review
suff
et
al
bryostatin
eg
bryostatin
b
r
oh
pettit
et
al
exhibit
antitumor
activ
sever
tumor
model
select
cytotox
leukemia
cell
line
suff
et
al
modul
immun
system
variou
way
vide
infra
antitumor
properti
extract
b
neritina
first
demonstr
use
murin
leukemia
suff
et
al
one
experi
tc
mgkg
observ
howev
cytotox
observ
kb
cell
line
use
routin
nci
project
monitor
fraction
activ
extract
reproduc
activ
could
achiev
evalu
extract
obtain
differ
collect
b
neritina
research
organ
put
asid
sever
year
ten
year
pass
sampl
could
found
suffici
potent
vitro
assay
reproduc
vivo
antitumor
assay
suffici
quantiti
permit
bioassayguid
isol
activ
compon
suff
et
al
bryostatin
also
discov
three
organ
b
neritina
grew
ie
bryozoan
amathia
convoluta
pettit
et
al
spong
lissodendoryx
isodictyali
pettit
et
al
tunic
aplidium
convoluta
pettit
et
al
earli
bryostatin
evalu
number
vivo
tumor
model
activ
demonstr
sever
experiment
leukemia
sarcoma
model
suff
et
al
howev
none
anim
cure
respect
tumor
time
similar
activ
observ
melanoma
mammari
colon
lung
cancer
profil
biolog
activ
encourag
result
first
mechanismofact
studi
report
begin
berkow
kraft
also
bryostatin
show
strong
specif
nci
diseasespecif
panel
human
cell
line
differ
ic
valu
sensit
resist
line
equal
greater
log
unit
suff
et
al
first
mechanist
studi
berkow
kraft
kraft
et
al
show
bryostatin
bind
phorbol
ester
receptor
human
polymorphonuclear
leukocyt
cell
equival
calcium
phospholipiddepend
protein
kinas
ie
protein
kinas
c
block
phorbol
esterinduc
macrophagelik
differenti
cell
although
bryostatin
unabl
induc
differenti
cell
decreas
cytoplasm
protein
kinas
c
activ
later
studi
bryostatin
found
inhibit
growth
lung
cancer
cell
inhibit
dna
replic
caus
transloc
protein
kinas
c
cytosol
membran
regul
protein
kinas
c
activ
similar
induc
phorbol
ester
howev
rel
high
concentr
bryostatin
block
inhibitori
effect
antirepl
action
phorbol
ester
therefor
relationship
growth
arrest
protein
kinas
c
activ
view
straightforward
one
addit
act
cytotox
antitumor
agent
antitumor
promot
bryostatin
modul
immun
system
presum
affect
protein
kinas
c
import
mediat
signal
transductionassoci
cell
regul
transform
one
studi
sever
bryostatin
recombin
human
granulocyt
macrophag
colonystimul
factor
rhgmcsf
found
stimul
format
granulocytemacrophag
pure
granulocyt
coloni
bone
marrow
howev
unlik
rhgmcsf
bryostatin
bryostatin
found
rapidli
activ
matur
neutrophil
involv
nonspecif
immun
defens
schindler
studi
conclud
bryostatin
may
repres
clinic
attract
agent
complement
compound
use
treat
clinic
situat
result
bone
marrow
failur
bryostatin
may
also
use
adjuv
clinic
situat
anoth
studi
trenn
et
al
bryostatin
like
phorbol
ester
found
lower
amount
recombin
requir
gener
antigenspecif
cytotox
tlymphocyt
vivo
prime
spleen
cell
prime
cytotox
tcell
use
combin
presenc
nonspecif
tcell
activ
con
caus
antigennonspecif
lysi
cell
tcell
clone
synerg
recombin
b
cell
stimulatori
factor
without
differenti
unprim
rest
tcell
cytotox
lymphocyt
studi
conclud
antineoplast
activ
bryostatin
may
relat
immunoenhanc
properti
clinic
may
use
combin
recombin
promot
tumor
reject
dose
suffici
low
avoid
side
effect
neither
studi
bryostatin
found
lymphotox
concentr
express
immunomodul
effect
current
licens
gr
pettitarizona
state
univers
cooper
research
develop
agreement
crada
nci
bristolmy
squibb
pursu
largescal
isol
bryostatin
develop
persino
respond
pettit
encourag
cancer
research
campaign
great
britain
conduct
preclin
toxicolog
small
anim
persino
clinic
trial
began
manchest
cambridg
england
februari
persino
bristolmy
squibb
plan
initi
studi
dog
persino
nci
plan
vivo
studi
anim
persino
sever
hundr
shallow
water
sampl
variou
marin
organ
collect
throughout
western
caribbean
organ
extract
tunic
trididemnum
solidum
van
name
found
activ
shipboard
assay
herp
simplex
cytotox
viral
host
cell
line
monkey
kidney
tissu
rinehart
et
al
subsequ
landbas
assay
tunic
extract
also
exhibit
vitro
activ
murin
leukemia
variou
rna
dna
virus
ie
vaccinia
influenza
coxsacki
equin
rhino
viru
three
compound
isol
initi
didemnin
c
contain
antivir
activ
cytotox
crude
extract
rinehart
et
al
rinehart
et
al
structur
relat
compound
didemnin
e
subsequ
isol
structur
elucid
total
didemnin
detect
munro
et
al
didemnin
cyclic
depsipeptid
five
amino
acid
unit
common
didemnin
largest
compound
seri
whose
structur
publish
contain
amino
acid
unit
includ
standard
amino
acid
lglu
lthr
lleu
lpro
methyl
amino
acid
dmeleu
unusu
group
llaclpro
isostatin
hydroxyisovalerylpropion
acid
isostatin
unit
origin
thought
statin
hydroxyisovalerylpropion
acid
tent
origin
assign
subsequ
revis
ewe
et
al
addit
antivir
activ
cytotox
didemnin
exhibit
antitumor
immunomodulatori
activ
antivir
activ
pursu
initi
origin
report
rinehart
et
al
rinehart
et
al
didemnin
b
exhibit
good
doserespons
relationship
virus
crude
extract
activ
vide
supra
subsequ
vitro
studi
reveal
activ
broad
rang
rna
virus
includ
rift
valley
fever
venezuelan
equin
encephalomyel
viru
yellow
fever
sandfli
fever
pichind
viru
canonico
et
al
vivo
activ
demonstr
didemnin
b
lethal
challeng
dna
viru
mous
vagin
herp
model
canonico
et
al
weed
stringfellow
rift
valley
fever
rna
viru
unfortun
didemnin
b
effect
vivo
herp
topic
applic
start
prior
infect
effect
appli
infect
given
intraperiton
gener
didemnin
found
toxic
suffici
select
antivir
therapi
munro
et
al
immunomodulatori
properti
didemnin
studi
initi
research
univers
arizona
montgomeri
zukoski
montgomeri
et
al
montgomeri
et
al
russel
et
al
first
publish
studi
group
montgomeri
zukoski
didemnin
b
found
inhibit
alloantigen
respons
mlr
inhibit
con
ainduc
blastogenesi
lymphocyt
inhibit
bacteri
lipopolysaccharid
lp
induc
blastogenesi
b
lymphocyt
nanogram
picogrammillilit
concentr
nontox
unstimul
lymphocyt
didemnin
b
also
inhibit
protein
synthesi
normal
rest
splenic
mononuclear
cell
concentr
much
greater
affect
con
aand
lpsinduc
mitogenesi
affect
rna
synthesi
microgrammillilit
concentr
didemnin
b
also
inhibit
splenomegali
vivo
simonsen
gvhr
mgkgday
howev
concentr
didemnin
b
mgkgday
caus
mortal
primarili
advers
effect
hepat
function
followup
vivo
studi
inhibit
lpsinduc
mitogenesi
conduct
montgomeri
et
al
montgomeri
et
al
observ
chang
bone
marrow
function
due
didemnin
b
thought
relat
increas
product
releas
lymphocyt
neutrophil
bone
marrow
studi
differ
research
group
investig
mechan
inhibit
tlymphocyt
prolifer
legru
et
al
didemnin
b
found
inhibit
lymphocyt
prolifer
cytostat
affect
mechan
inhibit
appear
distinct
cyclosporin
affect
lymphokin
product
vivo
studi
yield
mix
result
one
studi
didemnin
b
found
significantli
prolong
surviv
rat
heart
allograft
dose
low
mgkg
howev
longterm
surviv
rat
heart
allograft
could
achiev
even
nearleth
dosag
contrast
effect
cyclosporin
steven
et
al
anoth
studi
yuh
et
al
didemnin
b
evalu
mous
rat
heterotop
cardiac
transplant
model
mous
poplit
lymph
node
hyperplasia
assay
found
possess
low
therapeut
index
ie
dose
didemnin
b
prolong
allograft
surviv
inhibit
lymphocyt
prolifer
quit
toxic
evidenc
signific
revers
bodi
weight
loss
toxic
due
didemnin
b
appear
cumul
presum
relat
lipophil
therefor
accumul
compound
certain
bodi
tissu
latter
studi
conclud
vitro
potenc
didemnin
b
unfortun
suffici
predict
efficaci
immunosuppress
vivo
suitabl
mechan
action
ie
shown
clinic
use
agent
cyclosporin
highli
import
advanc
area
biolog
evalu
didemnin
antitumor
agent
cytotox
antitumor
properti
result
mechanismofact
studi
didemnin
previous
review
chun
et
al
munro
et
al
didemnin
b
potent
cytotoxin
ed
valu
ng
ml
respect
vivo
activ
establish
didemnin
b
ip
murin
leukemia
tc
mgkg
ip
ql
ip
murin
melanoma
tc
mgkg
ip
tc
mgkg
ip
ip
murin
sarcoma
tc
ql
didemnin
b
also
exhibit
vivo
activ
ip
yoshida
ascit
tumor
rat
tc
mgkg
ip
ql
rat
total
fimiani
vivo
efficaci
observ
experi
subcutan
sc
murin
mammari
tumor
sc
colon
tumor
ip
murin
leukemia
intraven
iv
lewi
lung
carcinoma
human
colon
tumor
xenograft
human
lung
tumor
xenograft
human
mammari
tumor
xenograft
didemnin
test
extens
vivo
tumor
model
experi
evalu
proven
efficaci
didemnin
b
antitumor
activ
murin
melanoma
found
didemnin
b
subcutan
intraven
oral
administr
none
vivo
experi
yield
longterm
survivor
dosag
experi
provid
greatest
treatment
valu
ie
mgkg
also
caus
greatest
amount
weight
loss
chun
et
al
didemnin
b
also
evalu
human
tumor
stem
cell
human
tumor
coloni
form
assay
use
fresh
human
tumor
surgic
biopsi
specimen
result
also
review
munro
et
al
chun
et
al
activ
nanogrammillilit
microgrammillilit
concentr
observ
carcinoma
breast
ovari
kidney
mesothelioma
sarcoma
ovarian
cancer
hairi
cell
leukemia
breast
cancer
oligodendroglioma
didemnin
b
appear
exert
antiprolif
effect
variou
cell
line
primarili
inhibit
protein
synthesi
lesser
extent
inhibit
dna
synthesi
review
chun
et
al
inhibit
protein
synthesi
relat
amino
acid
uptak
didemnin
b
bind
dna
compound
effect
exponenti
grow
cell
much
greater
extent
plateauphas
cell
low
dose
didemnin
b
stop
cell
progress
gi
boundari
cell
progress
g
gi
rel
unaffect
except
high
dose
complet
inhibit
cell
progress
growth
occur
didemnin
b
complet
phase
clinic
trial
anticanc
agent
dorr
et
al
doselimit
toxic
nausea
vomit
could
amelior
somewhat
pretreat
aggress
antiemet
regimen
object
antitumor
respons
observ
broad
phase
ii
clinic
trial
didemnin
b
antitumor
agent
ongo
persino
sesterterpenoid
manoalid
structur
relat
compound
obtain
marin
spong
luff
arietta
variabili
scheuer
compound
name
recognit
locat
chemistri
work
complet
manoa
valley
hawaii
although
manoalid
crude
methylen
chlorid
extract
deriv
demonstr
vitro
antibiot
activ
streptomyc
pyogen
staphylococcu
aureu
de
silva
scheuer
analges
antiinflammatori
activ
manoalid
faulkner
jacob
et
al
relat
seri
compound
albizati
et
al
kernan
et
al
elicit
substanti
scientif
pharmaceut
interest
first
total
synthesi
manoalid
relat
compound
secomanoalid
accomplish
soon
structur
publish
katsumura
et
al
thu
amelior
anticip
difficulti
regard
suppli
indepth
biolog
evalu
facilit
possibl
prepar
efficaci
analog
analges
activ
manoalid
demonstr
phenylquinoneinduc
writh
assay
mice
ed
mgkg
ip
jacob
et
al
manoalid
also
shown
activ
antagon
inflammatori
respons
mous
epidermi
induc
pma
potenc
greater
ed
standard
nonsteroid
compound
indomethacin
ed
less
hydrocortison
ed
burley
et
al
manoalid
like
hydrocortison
prevent
inflamm
respons
normal
induc
arachidon
acid
postul
compound
might
inhibit
enzym
reaction
locat
upstream
arachidon
acid
releas
prostaglandin
synthesi
hypothesi
support
part
vivo
time
cours
studi
show
manoalid
effect
appli
within
minut
pma
applic
earli
time
point
consid
normal
period
requir
inflammatori
reaction
manifest
specul
time
mechan
action
indomethacin
prevent
prostaglandin
product
inhibit
cyclooxygenas
pathway
hydrocortison
prevent
prostaglandin
product
inhibit
arachidon
acid
releas
led
hypothesi
manoalid
might
serv
inactiv
inhibit
variou
action
enzym
pla
one
studi
de
freita
et
al
manoalid
x
shown
prevent
neurotox
action
rat
phrenic
nervediaphragm
prepar
preincub
toxin
littl
minut
studi
manoalid
inhibit
hydrolysi
phosphatidylchohn
bee
venomderiv
pla
preincub
enzym
hour
subsequ
studi
demonstr
irrevers
reaction
ph
depend
jacob
manoalid
also
shown
inhibit
activ
pla
sourc
includ
cobra
venom
lombardo
denni
manoalid
block
hydrolysi
phosphatidylchohn
phosphatidylethanolamin
bee
venom
pla
manoalid
also
report
less
activ
pla
obtain
mammalian
microsom
prepar
guinea
pig
lung
uteru
rat
basophil
leukemia
cell
smooth
muscl
pla
obtain
cobra
venom
bennett
et
al
result
suggest
pla
alon
sole
princip
intracellular
target
manoalid
manoalid
found
capabl
inhibit
phosphoinositidespecif
phospholipas
c
plc
within
ic
valu
rang
inactiv
calcium
ph
depend
irrevers
purport
mechan
action
manoalid
antiinflammatori
activ
appear
involv
direct
bind
molecul
pla
manoalid
observ
form
chromophor
mix
bee
venom
pla
glaser
jacob
similar
reaction
occur
manoalid
incub
monomer
lysin
cystein
tryptophan
respect
nalphaaminoblock
analog
seri
straightforward
eleg
experi
correl
chromophor
product
specif
amino
acid
residu
modifi
upon
bind
manoalid
pla
correspond
enzymat
activ
guid
team
discoveri
result
subsequ
experi
indic
lysin
residu
avail
modif
manoalid
three
actual
modifi
upon
bind
manoalid
bee
venom
pla
contrast
modif
four
six
lysin
present
cobra
venom
pla
lombardo
denni
subsequ
investig
reveal
number
structur
activ
relationship
associ
manoalid
molecul
relat
analog
may
prove
use
determin
exact
natur
bind
manoalid
pla
includ
ring
system
select
variou
sourc
pla
aldehyd
irrevers
pla
bind
hydrophob
alkyl
region
molecul
cooper
bind
ring
system
pla
molecul
manoalid
mechan
inhibit
phospholipid
hydrolysi
led
number
investig
util
probe
studi
role
import
phospholipas
role
ca
signal
transductionmedi
event
cellular
growth
replic
key
compon
mani
inflammatori
mediat
growth
factor
abil
bind
cellular
receptor
turn
stimul
phosphoinositid
turnov
ca
mobil
part
signal
transduct
pathway
major
role
plc
process
includ
activ
pip
give
rise
inositol
ip
diacylglycerol
dag
berridg
ip
serv
second
messeng
bind
receptor
rough
endoplasm
reticulum
caus
releas
ca
intracellular
store
dag
hand
physiolog
receptor
protein
kinas
c
import
second
messeng
enzym
involv
regul
cellular
prolifer
manoalid
primari
pharmacolog
action
involv
inhibit
pla
activ
previous
note
manoalid
less
potent
measur
inhibit
plc
activ
prompt
investig
role
antagonist
calciummedi
signal
transductionmedi
control
cellular
growth
regul
manoalid
found
potent
inhibitor
ca
mobil
sever
cell
line
wheeler
et
al
epiderm
growth
factor
egf
stimul
rise
intracellular
ca
human
epidermoid
carcinoma
cell
manoalid
block
egfmedi
entri
releas
ca
intracellular
store
timedepend
manner
ic
howev
product
inositol
monophosph
phosphoinositid
metabol
coincid
egfmedi
respons
manoalid
also
block
thyrotropinreleas
hormon
trh
depend
releas
ca
intracellular
store
gh
rat
pituitari
cell
minut
minut
without
concomit
inhibit
format
inositol
phosphat
pip
addit
manoalid
also
inhibit
k
depolarizationactiv
ca
channel
cell
activ
channel
bay
ic
manoalid
also
inhibit
ca
uptak
murin
splenocy
stimul
concanavalin
timeand
temperaturedepend
manner
ic
thu
indic
least
cell
examin
studi
manoalid
inhibitori
action
appear
involv
blockag
calcium
channel
role
manoalid
regul
variou
eicosanoid
precursor
role
play
inflammatori
process
began
establish
sever
year
ago
manoalid
inhibit
product
prostaglandin
e
pge
dosedepend
fashion
pmazymosan
stimul
murin
periton
macrophag
releas
leukotrien
q
ltc
murin
periton
macrophag
stimul
calcium
ionophor
similarli
inhibit
curious
ltc
product
enhanc
manoalid
cell
stimul
zymosan
pge
ltc
product
reduc
resid
unstimul
mous
periton
macrophag
indic
direct
inhibitori
effect
manoalid
pathway
addit
releas
harachidon
acid
shown
partial
reduc
inhibit
presenc
manoalid
result
point
possibl
manoalid
mechan
action
appear
includ
follow
inhibit
plc
pla
result
inhibit
arachidon
releas
inhibit
pge
product
blockag
ca
mobil
subsequ
studi
lister
et
al
confirm
extend
find
mayer
use
murin
macrophag
cell
line
lister
found
manoalid
unlik
pla
inhibitor
equal
effect
inhibit
intracellular
extracellular
isol
pla
manoalid
continu
use
tool
help
elucid
complex
interplay
eicosanoid
regul
membran
phospholipidsign
transduct
mediat
event
vivo
antiinflammatori
activ
compound
relat
analog
suggest
potenti
clinic
use
compound
disord
manifest
alter
product
inflammatori
eicosanoid
product
ie
prostaglandin
vitro
studi
jacobson
et
al
manoalid
demonstr
inhibit
pla
human
synovi
fluid
site
patholog
damag
rheumatoid
arthriti
demonstr
manoalid
abil
inhibit
releas
elastas
human
neutrophil
stimul
fmlp
fmetleuph
underscor
potenti
compound
potenti
next
gener
antiinflammatori
agent
past
year
tremend
number
synthet
analog
manoalid
prepar
lee
lee
maullem
et
al
includ
manoalogu
reynold
et
al
cho
current
manoalid
select
analog
evalu
clinic
trial
topic
antiinflammatori
agent
r
jacob
person
commun
pseudopterosin
seri
tricycl
diterpen
glycosid
al
isol
caribbean
gorgonian
pseudopterogorgia
elisabetha
look
et
al
roussi
et
al
base
biolog
activ
crude
extract
pseudopterosin
contain
attach
diterpen
group
pseudopterosin
b
structur
ident
except
xylopyranos
monoacetyl
variou
hydroxyl
moieti
pseudopterosin
g
j
diastereom
contain
regioisomer
acet
group
attach
pseudopterosin
k
l
also
contain
group
attach
case
l
monoacetyl
howev
diastereom
oh
oh
group
cl
pseudopterosin
e
f
contain
ident
diterpenoid
group
found
howev
e
contain
attach
f
contain
biolog
activ
first
report
purifi
compound
describ
antimicrobi
activ
cytotox
direct
toward
fertil
egg
california
sea
urchin
ettouati
jacob
jacob
et
al
jacob
wilson
howev
potent
antiinflammatori
analges
activ
pseudopterosin
look
et
al
drove
biolog
chemic
character
compound
initi
studi
look
et
al
indic
pseudopterosin
significantli
potent
block
phorbol
myrist
acet
topic
induc
inflammatori
respons
mous
skin
k
x
compar
standard
antiinflammatori
drug
indomethacin
mm
concentr
pseudopterosin
greater
inactiv
hydrolysi
phosphatidyl
cholin
phospholipas
pla
bee
venom
liver
microsom
prepar
howev
pancreat
pla
activ
shown
inhibit
ic
valu
rang
pseudopterosin
also
found
potent
indomethacin
analges
block
stretchflex
respons
phenylquinon
inject
mice
ed
obtain
mgkg
pseudopterosin
versu
mgkg
indomethacin
pseudopterosin
mimic
morphin
electr
driven
prepar
antagon
histamin
bradykinin
concentr
prevent
phorbol
dibutyr
inhibit
bradykinininduc
contract
guinea
pig
ileum
pseudopterosin
express
vivo
toxic
acut
toxic
rang
mgkg
mice
pseudopterosin
e
demonstr
low
acut
toxic
mice
ld
mgkg
antiinflammatori
potenc
equival
pseudopterosin
roussi
et
al
addit
preliminari
biolog
activ
pseudopterosin
e
suggest
uniqu
mechan
action
via
inhibit
leukotrien
synthesi
precis
mechan
action
compound
unknown
molecul
seem
serv
potenti
antagonist
lipoxygenas
enzym
involv
arachidon
cascad
superior
vivo
vitro
antiinflammatori
activ
pseudopterosin
e
prompt
sever
investig
possibl
derivat
synthesi
molecul
attempt
made
obtain
compound
interconvers
pseudopterosin
e
roussi
et
al
howev
ineffici
glycosid
reaction
lead
poor
yield
compound
first
total
enantiospecif
synthesi
pseudopterosin
e
report
direct
attach
lfucos
unit
aglycon
via
novel
method
corey
carpino
method
synthesi
pseudopterosin
similarli
describ
investig
reveal
altern
pathway
obtain
glycosyl
form
aglycon
pseudopterosin
e
broka
et
al
ganguli
et
al
import
role
glycosyl
molecul
underlin
fact
aglycon
portion
alon
activ
vivo
vitro
synthesi
compound
well
hand
work
continu
synthesi
variou
analog
compound
determin
precis
mechan
action
antiinflammatori
activ
r
jacob
person
commun
present
evid
indic
one
primari
mechan
antiinflammatori
effect
pseudopterosin
lie
abil
select
block
degranul
leukotrien
product
human
polymorphonuclear
neutrophil
r
jacob
person
commun
model
compound
pseudopterosin
e
effect
eicosanoid
biosynthesi
cultur
mous
periton
macrophag
r
jacob
person
commun
current
pseudopterosin
undergo
clinic
evalu
topic
use
r
jacob
person
commun
cytosin
arabinosid
arac
studi
caribbean
spong
sterol
w
bergmann
cowork
earli
bergmann
burk
feeney
cohen
nucleosid
spongouridin
spongothymidin
discov
serendipit
found
possess
antivir
activ
discoveri
aid
develop
antitumor
agent
gener
nucleosid
antivir
sporad
synthet
analog
effort
improv
activ
compound
cytosin
arabinosid
arac
introduc
nearli
year
later
clinic
use
antitumor
agent
bodey
et
al
nearli
year
later
adenin
arabinosid
araa
approv
use
antivir
agent
buchanan
hess
cytosin
arabinosid
produc
synthet
current
distribut
indic
acut
nonlymphocyt
leukemia
chronic
myelocyt
leukemia
mening
leukemia
physician
desk
refer
adenin
arabinosid
obtain
ferment
cultur
streptomyc
antibioticu
current
distribut
physician
desk
refer
intraven
administr
viraa
indic
treatment
herp
simplex
viru
enceph
herp
simplex
infect
newborn
herp
zoster
viru
due
reactiv
varicelarost
viru
infect
immunosuppress
patient
ointment
use
topic
treatment
epitheli
kerat
caus
herp
simplex
subsequ
secondand
thirdgener
nucleosid
ie
acyclovir
azt
dideoxycytidin
highli
use
antivir
agent
object
medicin
chemistri
studi
find
even
efficaci
select
compound
contrast
biolog
activ
compound
terrestri
organ
consider
amount
work
done
success
achiev
knowledg
base
biolog
inform
compound
marin
organ
limit
howev
compound
studi
detail
success
rate
high
potenti
consider
past
three
decad
novel
compound
describ
marin
organ
review
faulkner
faulkner
faulkner
faulkner
faulkner
faulkner
faulkner
possess
strike
biolog
activ
describ
chapter
addit
recent
report
result
marin
extract
screen
strongli
suggest
marin
environ
hold
promis
continu
high
abund
biolog
activ
compound
munro
et
al
marin
natur
product
due
unriv
degre
structur
novelti
serv
inspir
mani
great
synthet
achiev
organ
chemistri
thu
great
structur
novelti
high
degre
biolog
activ
associ
group
substanc
past
year
new
marinederiv
compound
began
nce
new
chemic
entiti
unit
state
market
current
role
marin
natur
product
therapeut
regim
must
consid
light
drug
discoveri
develop
whole
given
time
capit
invest
requir
discov
develop
market
new
drug
niel
natur
consequ
therapeut
agent
today
market
part
result
research
develop
effort
year
henc
unfortun
much
publish
biolog
screen
effort
time
period
marinederiv
compound
mostli
classic
inde
marinederiv
compound
current
clinic
interest
see
section
product
marin
drug
discoveri
program
smaller
scope
number
exist
today
current
industri
marin
drug
discoveri
effort
initi
within
last
year
field
begin
evolv
state
rel
matur
total
chronolog
recent
marin
drug
discoveri
effort
yet
run
cours
consider
numer
paramet
drug
discoveri
also
reconcil
current
minor
role
play
marin
agent
chemotherapi
substanc
pharmacolog
test
pharmaceut
industri
reuben
wittcoff
overal
composit
total
somewhat
unclear
sinc
like
compris
numer
sourc
extract
ferment
product
natur
substanc
pure
synthet
etc
statist
comparison
must
interpret
caution
clear
howev
even
today
heighten
level
marinederiv
compound
extract
screen
thousand
per
year
perhap
repres
small
portion
amount
consider
scope
therapeut
area
screen
show
parallel
situat
earli
marin
screen
effort
focus
except
area
antitumor
cytotox
antivir
antimicrobi
area
repres
portion
full
rang
human
diseas
area
today
addit
investig
marin
product
immunomodul
inflamm
cardiovascular
central
nervou
system
hypertens
name
well
underway
effort
set
stage
marin
compound
play
increasingli
import
role
diseas
chemotherapi
year
come
seen
overal
research
effort
marin
drug
discoveri
rise
briefli
consid
sever
possibl
scenario
marin
natur
product
may
lead
therapeut
agent
success
drug
diseas
aid
certain
form
cancer
alzheim
diseas
other
truli
effect
form
chemotherapi
exist
unoptim
natur
product
may
compris
suitabl
treatment
case
acut
need
effect
agent
would
provid
drive
forc
acceler
clinic
investig
rel
complex
natur
occur
agent
usual
commerci
scenario
natur
product
biolog
activ
structur
complex
found
microorgan
produc
larg
quantiti
ferment
found
plant
produc
larg
quantiti
cultiv
incent
great
enough
total
synthesi
complex
natur
product
undertaken
exampl
immun
suppress
jone
et
al
nakatsuka
et
al
contrast
pure
didemnin
b
bryostatin
obtain
clinic
trial
massiv
field
collect
sourc
organ
trididemnum
solidum
bugula
neritina
schaufelberg
et
al
respect
didemnin
b
bryostatin
serv
well
illustr
central
problem
marin
drug
develop
compound
suppli
biolog
rich
marin
environ
well
appreci
prospect
usual
good
produc
larg
amount
kilogram
marin
compound
use
field
collect
organ
abund
marin
organ
collect
amount
addit
complic
wellestablish
variat
chemistri
within
speci
function
geograph
locat
thu
select
case
highli
abund
organ
ie
spong
bryozoan
gorgonian
alga
extrem
largescal
collect
possibl
even
environment
consequ
sever
therefor
case
might
possibl
produc
amount
marin
compound
suffici
preliminari
clinic
trial
gram
quantiti
collect
sourc
organ
approach
produc
quantiti
need
extend
trial
market
ten
kilogram
sever
excit
new
technolog
hold
promis
solv
suppli
problem
ie
spong
cell
cultur
aquacultur
presum
current
technolog
chemic
synthesi
microbi
ferment
provid
first
solut
ferment
mainstay
pharmaceut
industri
compound
product
mani
case
provid
suppli
structur
complex
antibiot
antitumor
antibiot
immun
suppress
econom
inaccess
chemic
synthesi
ferment
marin
microorgan
may
provid
addit
benefit
outsid
drug
develop
exampl
cultur
thermophil
bacteria
isol
marin
geotherm
site
borman
whose
thermal
robust
enzym
may
potenti
util
industri
catalyst
product
fuel
pharmaceut
specialti
chemic
inde
origin
sever
bioactiv
marin
natur
product
isol
spong
stierl
et
al
elyakov
et
al
macroorgan
tamplin
trace
microbi
symbiont
report
success
cultur
microorgan
becom
frequent
central
role
chemic
synthesi
drug
develop
certainli
requir
illustr
chemic
synthesi
modif
natur
compound
yield
major
chemotherapeut
agent
us
market
especi
certain
diseas
area
due
inher
suppli
problem
describ
previous
even
case
origin
parent
compound
might
suitabl
drug
candid
chemic
synthesi
still
like
becom
mean
suitabl
quantiti
produc
advanc
clinic
investig
market
natur
outgrowth
synthet
effort
investig
analog
part
medicin
chemistri
effort
bring
forth
anoth
scenario
structur
lead
mani
marin
natur
product
strike
molecular
complex
match
biolog
activ
certainli
molecul
pali
toxin
armstrong
et
al
armstrong
et
al
mycalamid
hong
kishi
onnamid
hong
kishi
okada
acid
isob
et
al
repres
tremend
challeng
synthet
organ
chemist
fact
mani
complex
marinederiv
molecul
synthes
testimoni
great
advanc
made
scienc
art
synthet
chemistri
howev
even
compound
type
possess
medicin
valu
competit
current
agent
structur
complex
greatli
lower
likelihood
econom
viabl
synthesi
like
bioactiv
complex
marin
metabolit
serv
lead
structur
medicin
chemistri
effort
program
type
design
sever
goal
mind
least
discoveri
structur
analog
exhibit
improv
therapeut
attribut
simpler
ie
econom
chemic
structur
well
tri
secur
suffici
broad
appropri
patent
coverag
illustr
case
scenario
avail
case
manoalid
see
section
compound
isol
marin
spong
luffariella
variabili
de
silva
scheuer
manoalid
found
specif
inhibitor
phospholipas
c
current
develop
antiinflammatori
agent
see
section
synthesi
evalu
extens
seri
analog
undertaken
sever
pharmaceut
compani
work
report
patent
literatur
well
open
literatur
garst
et
al
katsumura
et
al
lee
lee
maullem
et
al
consequ
manoalid
select
synthet
analog
evalu
topic
antiinflammatori
agent
clinic
trial
r
jacob
person
commun
enorm
invest
money
us
million
time
year
involv
develop
new
therapeut
agent
perform
well
desir
develop
better
analog
becom
import
therefor
consider
effort
expend
prepar
secondand
thirdgener
compound
even
activ
less
toxic
similar
situat
araa
arac
scenario
certainli
also
appli
newli
discov
marinederiv
compound
analog
develop
therapeut
agent
highlight
sourc
collect
method
strategi
structur
respect
biolog
activ
numer
marinederiv
compound
believ
shown
marin
environ
rich
viabl
sourc
structur
unusu
biolog
activ
compound
therapeut
potenti
believ
touch
mani
import
issu
relat
marinederiv
therapeut
agent
includ
discoveri
approach
supplysynthesi
versu
collect
ferment
structureact
optim
studi
appropri
collabor
academ
research
industri
research
develop
group
final
believ
import
key
realiz
therapeut
potenti
marin
natur
product
patienc
discoveri
academ
govern
industri
research
group
marinederiv
compound
satisfactori
biolog
profil
becom
lead
compound
may
occur
tomorrow
may
occur
year
discov
optim
compound
may
take
anoth
year
reach
market
wait
worthwhil
scientif
commerci
numer
inevit
spinoff
continu
discoveri
develop
biochem
probe
tool
better
understand
biolog
particular
diseas
state
base
uniqu
biolog
activ
marinederiv
compound
better
understand
marin
organ
produc
compound
respect
environ
advanc
spectroscopi
synthesi
consequ
conduct
research
often
complex
structur
unusu
molecul
